Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer

Yun Fan(Zhejiang Cancer Hospital), Xuehua Zhu(AstraZeneca (Germany)), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuesong Lu(AstraZeneca (Singapore)), Yanjun Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Haiyan Xu(AstraZeneca (Singapore)), Jingyan Ding(AstraZeneca (Germany)), Xin Ye(AstraZeneca (Germany)), Luo Fang(Zhejiang Cancer Hospital), Zhiyu Huang(Zhejiang Cancer Hospital), Lei Gong(Zhejiang Cancer Hospital), Hongyang Lu(Zhejiang Cancer Hospital), Weimin Mao(Zhejiang Cancer Hospital), Min Hu(AstraZeneca (Germany))
Clinical Cancer Research
October 13, 2017
Cited by 66Open Access
Full Text

Abstract

Abstract Purpose: Leptomeningeal metastasis (LM) is a detrimental complication of non–small cell lung cancer (NSCLC) and associated with poor prognosis. However, the underlying mechanisms of the metastasis process are still poorly understood. Experimental Design: We performed next-generation panel sequencing of primary tumor tissue, cerebrospinal fluid (CSF), and matched normal controls from epidermal growth factor receptor (EGFR) mutation-positive NSCLC patients with LM. Results: The status of EGFR-activating mutations was highly concordant between primary tumor and CSF. PIK3CA aberrations were high in these patients, implicating an association with LM risk. Intriguingly, low overlapping of somatic protein-changing variants was observed between paired CSF and primary lesions, exhibiting tumor heterogeneity and genetic divergence. Moreover, genes with CSF-recurrent genomic alterations were predominantly involved in cell-cycle regulation and DNA-damage response (DDR), suggesting a role of the pathway in LM development. Conclusions: Our study has shed light on the genomic variations of NSCLC-LM, demonstrated genetic heterogeneity and divergence, uncovered involvement of cell-cycle and DDR pathway, and paved the way for potential therapeutic approaches to this unmet medical need. Clin Cancer Res; 24(1); 209–16. ©2017 AACR.


Related Papers

No related papers found

Powered by citation graph analysis